TOKYO -- Japanese drugmaker Eisai will acquire a Chinese generics company in a deal worth 500 million yuan ($78.2 million), gaining a bigger foothold in the world's second-largest pharmaceutical market.
Business
TOKYO -- Japanese drugmaker Eisai will acquire a Chinese generics company in a deal worth 500 million yuan ($78.2 million), gaining a bigger foothold in the world's second-largest pharmaceutical market.
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.